
BLRX
BioLine RX Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.480
Open
4.450
VWAP
4.33
Vol
34.52K
Mkt Cap
11.15B
Low
4.250
Amount
149.42K
EV/EBITDA(TTM)
--
Total Shares
79.94M
EV
6.43M
EV/OCF(TTM)
--
P/S(TTM)
0.49
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
892.67K
-92.4%
--
--
776.67K
-84.29%
--
--
661.33K
-87.74%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by -12.74% over the past three months. During the same period, the stock price has changed by 50.34%.
Revenue Estimates for FY2025
Revise Downward

-12.74%
In Past 3 Month
Stock Price
Go Up

+50.34%
In Past 3 Month
2 Analyst Rating

335.78% Upside
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 19.00 USD with a low forecast of 12.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

335.78% Upside
Current: 4.360

Low
12.00
Averages
19.00
High
26.00

335.78% Upside
Current: 4.360

Low
12.00
Averages
19.00
High
26.00
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
2025-04-02
Reason
Jones Trading
Justin Walsh
Price Target
n/a
2025-04-02
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$9 → $26
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9 → $26
2025-03-31
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$21 → $9
2024-11-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21 → $9
2024-11-25
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2024-11-06
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2024-11-06
Reiterates
Strong Buy
Reason
Jones Trading
Justin Walsh
Strong Buy
Initiates
$2
2024-09-04
Reason
Jones Trading
Justin Walsh
Price Target
$2
2024-09-04
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -2.70, compared to its 5-year average forward P/E of -1.43. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.43
Current PE
-2.70
Overvalued PE
0.10
Undervalued PE
-2.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.05
Undervalued EV/EBITDA
-2.52
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
12.79
Current PS
4.95
Overvalued PS
56.29
Undervalued PS
-30.70
Financials
Annual
Quarterly
FY2025Q1
YoY :
-96.28%
255.00K
Total Revenue
FY2025Q1
YoY :
-50.41%
-2.39M
Operating Profit
FY2025Q1
YoY :
-836.64%
5.13M
Net Income after Tax
FY2025Q1
0.00
EPS - Diluted
FY2025Q1
YoY :
-81.68%
-2.59M
Free Cash Flow
FY2025Q1
YoY :
+10.03%
86.67
Gross Profit Margin - %
FY2025Q1
-144.93
FCF Margin - %
FY2025Q1
YoY :
-19908.77%
2.01K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BLRX News & Events
Events Timeline
2025-05-30 (ET)
2025-05-30
08:43:01
BioLineRx upgraded to Buy from Hold at JonesResearch

2025-05-30
07:05:01
BioLineRx announces new data from Phase 2 combination trial of motixafortide

2025-05-27 (ET)
2025-05-27
07:03:06
BioLineRx reports Q1 EPS 0c vs. 0c last year

Sign Up For More Events
Sign Up For More Events
News
4.0
05-31NASDAQ.COMJones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)
4.5
05-30BenzingaDow Edges Higher; Dell Shares Fall After Q1 Results
9.0
05-30BenzingaWhy Is Nano-Cap BioLineRx Stock Surging On Friday?
Sign Up For More News
People Also Watch

DC
Dakota Gold Corp
4.230
USD
+2.67%

GASS
StealthGas Inc
6.580
USD
+0.92%

SMID
Smith-Midland Corp
36.610
USD
-1.77%

MFIN
Medallion Financial Corp
9.450
USD
+1.72%

BLFY
Blue Foundry Bancorp
9.120
USD
+0.11%

ODV
Osisko Development Corp
2.460
USD
+0.82%

SKIN
Beauty Health Co
1.660
USD
+4.40%

FXNC
First National Corp
21.010
USD
+1.69%

OVLY
Oak Valley Bancorp
27.900
USD
+1.20%

FVCB
FVCBankcorp Inc
13.240
USD
+0.23%
FAQ

What is BioLine RX Ltd (BLRX) stock price today?
The current price of BLRX is 4.36 USD — it has decreased -2.46 % in the last trading day.

What is BioLine RX Ltd (BLRX)'s business?

What is the price predicton of BLRX Stock?

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for BioLine RX Ltd (BLRX)'s fundamentals?

How many employees does BioLine RX Ltd (BLRX). have?
